Gold is 2025’s best performer. UBS sees more upside
Ashiya Mona, a director at Disc Medicine, Inc. (NASDAQ:IRON), recently executed a series of stock sales amounting to a total of $16.97 million. The transactions, which took place over several days, involved the sale of common stock at prices ranging from $54.01 to $55.05 per share. The sales occurred as the company, currently valued at $1.86 billion, trades near $54, significantly above its 52-week low of $25.60.
On March 10, Mona sold a total of 192,146 shares, with prices averaging around $54.29. Additional sales occurred on March 11, with 27,056 shares sold at an average price of $54.01. The following day, March 12, saw the sale of 72,449 shares at $54.44 and 1,769 shares at $55.05. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $75 to $118.
After these transactions, Mona’s remaining holdings in Disc Medicine are divided among various entities, including OrbiMed Private Investments VI, LP, OrbiMed Private Investments VIII, LP, and OrbiMed Genesis Master Fund, L.P., as detailed in footnotes accompanying the filing. The sales reflect a strategic adjustment in Mona’s investment in the company, though the director continues to hold significant shares through these entities.
In other recent news, Disc Medicine has been the focus of several analyst updates and developments. Cantor Fitzgerald has maintained its Overweight rating on Disc Medicine with a price target of $99, reflecting recent financial updates, including a public offering that increased the number of shares. Scotiabank (TSX:BNS) raised its price target for the company to $75, noting the company’s plans for a New Drug Application for bitopertin in treating erythropoietic protoporphyria (EPP) by the second half of 2025. The analyst highlighted the potential for a 2026 launch if the FDA grants priority review.
TD Cowen initiated coverage on Disc Medicine with a Buy rating, citing optimism about the potential market penetration of bitopertin and the significant opportunity for another treatment, 0974, in the myelofibrosis anemia space. Stifel has also increased its price target to $94, maintaining a Buy rating, following the company’s authorization to submit an NDA for bitopertin for accelerated approval. The Stifel analyst expressed an 85% chance of approval, with a potential commercial launch in 2026.
These developments highlight the company’s ongoing efforts in drug development and market expansion. Disc Medicine’s recent capital raise has strengthened its financial position, extending its cash runway into 2028. Analysts remain optimistic about the company’s growth trajectory, given the promising pipeline and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.